Sex hormone-regulatedcmg2is involved in breast and prostate cancer progression

Fang, Ziqian, Killick, Charlotte, Halfpenny, Cerith, Frewer, Natasha, Frewer, Kathryn A., Ruge, Fiona, Jiang, Wen G. ORCID: https://orcid.org/0000-0002-3283-1111 and Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409 2022. Sex hormone-regulatedcmg2is involved in breast and prostate cancer progression. Cancer Genomics & Proteomics 19 (6) , pp. 703-710. 10.21873/cgp.20353

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (5MB) | Preview

Abstract

Background/Aim: Capillary morphogenesis gene 2 (CMG2) is involved in prostate and breast cancer progression. This study aimed to investigate sex hormone receptor-mediated regulation of CMG2 in breast and prostate cancer, and its implication in disease progression. Materials and Methods: Expression of CMG2, oestrogen receptor (ER) and androgen receptor (AR) was determined in breast and prostate cancer cell lines, respectively, using real-time quantitative PCR (QPCR) and western blot. Association between CMG2 and sex hormone receptors was analysed in a number of transcriptome datasets. Immunochemical staining was performed in tissue microarrays of breast cancer (BR1505D) and prostate cancer (PR8011A). CMG2 expression was determined in 17β-oestradiol treated breast cancer cells and AR over-expressing prostate cancer cells. Results: CMG2 was found to be inversely correlated with sex hormone receptors in breast and prostate cancer. Lower expression of CMG2 was associated with a poor prognosis in ER (+) breast cancer but not ER (−) tumours. Both ER (+) breast cancer cell lines and AR (+) prostate cancer cell lines presented lower expression of CMG2, which was increased following sex hormone deprivation. Exposure to 17-β-oestradiol and AR over-expression repressed CMG2 expression in breast cancer and prostate cancer cell lines, respectively. Conclusion: CMG2 is inversely correlated with ER and AR status in breast and prostate cancer, respectively. ER and AR mediate repression of CMG2 expression in corresponding cancerous cells.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	International Institute of Anticancer Research
ISSN:	1109-6535
Date of First Compliant Deposit:	21 December 2022
Date of Acceptance:	23 August 2022
Last Modified:	15 May 2023 20:38
URI:	https://orca.cardiff.ac.uk/id/eprint/155081

Actions (repository staff only)

Edit Item